{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FGFR3+Gene+Fusions",
    "query": {
      "condition": "FGFR3 Gene Fusions"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T05:44:06.355Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05544552",
      "title": "Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Urothelial Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Solid Tumor",
        "Urothelial Carcinoma",
        "Solid Tumor, Adult",
        "Bladder Cancer",
        "Non-muscle-invasive Bladder Cancer",
        "FGFR3 Gene Mutation",
        "FGFR3 Gene Alteration",
        "Advanced Solid Tumor",
        "Advanced Urothelial Carcinoma",
        "Urinary Tract Cancer",
        "Urinary Tract Tumor",
        "Urinary Tract Carcinoma"
      ],
      "interventions": [
        {
          "name": "TYRA-300",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyra Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 310,
      "start_date": "2022-11-22",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-05-22T05:44:06.355Z",
      "location_count": 7,
      "location_summary": "Boston, Massachusetts • Worchester, Massachusetts • New York, New York + 4 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Worchester",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05544552"
    },
    {
      "nct_id": "NCT01752920",
      "title": "Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Derazantinib low dose range",
          "type": "DRUG"
        },
        {
          "name": "Derazantinib middle dose range",
          "type": "DRUG"
        },
        {
          "name": "Derazantinib high dose range",
          "type": "DRUG"
        },
        {
          "name": "Derazantinib at recommended phase 2 dose (RP2D)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Basilea Pharmaceutica",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2012-12-10",
      "completion_date": "2018-08-28",
      "has_results": true,
      "last_update_posted_date": "2023-06-05",
      "last_synced_at": "2026-05-22T05:44:06.355Z",
      "location_count": 8,
      "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Detroit, Michigan + 5 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01752920"
    },
    {
      "nct_id": "NCT07265947",
      "title": "Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Low Grade Upper Tract Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Dabogratinib (TYRA-300) 60mg",
          "type": "DRUG"
        },
        {
          "name": "Dabogratinib (TYRA-300) 80mg",
          "type": "DRUG"
        },
        {
          "name": "Dabogratinib (TYRA-300) TBD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyra Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 230,
      "start_date": "2025-12-22",
      "completion_date": "2030-11",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-22T05:44:06.355Z",
      "location_count": 5,
      "location_summary": "Lisle, Illinois • Jeffersonville, Indiana • Cleveland, Ohio + 2 more",
      "locations": [
        {
          "city": "Lisle",
          "state": "Illinois"
        },
        {
          "city": "Jeffersonville",
          "state": "Indiana"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07265947"
    },
    {
      "nct_id": "NCT06995677",
      "title": "Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Low-grade NMIBC",
        "FGFR Gene Amplification",
        "FGFR Gene Alterations",
        "FGFR3 Gene Alteration",
        "FGFR3 Gene Mutation",
        "FGFR3 Gene Fusions"
      ],
      "interventions": [
        {
          "name": "TYRA-300 60mg",
          "type": "DRUG"
        },
        {
          "name": "TYRA-300 50mg",
          "type": "DRUG"
        },
        {
          "name": "TYRA-300 Dose TBD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyra Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2025-06-27",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-05-22T05:44:06.355Z",
      "location_count": 28,
      "location_summary": "Homewood, Alabama • Little Rock, Arkansas • Murrieta, California + 25 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Chicago Ridge",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06995677"
    },
    {
      "nct_id": "NCT06915753",
      "title": "Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Hepatocellular Carcinoma",
        "Solid Tumors",
        "Solid Tumor, Adult",
        "FGFR Gene Amplification",
        "FGFR Gene Alterations",
        "FGFR3 Gene Alteration",
        "FGFR3 Gene Mutation",
        "Advanced Solid Tumors",
        "FGFR4 Gene Mutation",
        "FGFR4 Gene Fusions",
        "FGF19 Gene Amplification",
        "FGF19 Gene Overexpression",
        "FGFR3 Gene Fusions",
        "Locally Advanced Unresectable Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "TYRA-430",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyra Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2025-04-24",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2025-11-20",
      "last_synced_at": "2026-05-22T05:44:06.355Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06915753"
    },
    {
      "nct_id": "NCT06777316",
      "title": "A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Intrahepatic Cholangiocarcinoma (Icc)",
        "Cholangiocarcinoma",
        "Other Solid Tumors, Adult",
        "FGFR2 Gene Fusion/Rearrangement",
        "FGFR2 Gene Amplification",
        "FGFR2 Gene Short Variants",
        "FGFR3 Gene Fusion/Rearrangement",
        "FGFR3 Gene Amplification",
        "FGFR3 Gene Short Variants",
        "FGFR2 Genetic Alterations",
        "FGFR3 Genetic Alterations",
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "CGT4859",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cogent Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2025-01-22",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-05-22T05:44:06.355Z",
      "location_count": 12,
      "location_summary": "Palo Alto, California • Jacksonville, Florida • Tampa, Florida + 9 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06777316"
    },
    {
      "nct_id": "NCT04919642",
      "title": "Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cholangiocarcinoma",
        "FGFR2 Fusion",
        "FGFR2 Gene Mutation",
        "FGFR1 Alteration",
        "FGFR3 Alteration"
      ],
      "interventions": [
        {
          "name": "TT-00420",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TransThera Sciences (Nanjing), Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2021-12-07",
      "completion_date": "2024-02-28",
      "has_results": false,
      "last_update_posted_date": "2024-06-25",
      "last_synced_at": "2026-05-22T05:44:06.355Z",
      "location_count": 32,
      "location_summary": "Anchorage, Alaska • Duarte, California • Santa Monica, California + 25 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04919642"
    }
  ]
}